XML 16 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2020
Jun. 30, 2020
Jun. 30, 2019
Current assets:      
Cash and cash equivalents $ 117.0 $ 163.7 $ 93.2
Marketable investment securities 33.7 54.1 43.7
Prepaid expenses 11.7 13.8 16.6
Inventory 27.1 29.1 31.4
Trade accounts receivable 89.5 68.1 133.9
Prepaid taxes 108.4 0.0 25.1
Other receivables 2.0 2.9 4.7
Total current assets 389.4 331.7 348.6
Property, plant and equipment, net 40.7 37.0 57.3
Operating lease right-of-use assets 59.7 66.0 0.0
Long-term marketable investment securities 21.0 37.0 54.9
Intangibles, net 576.5 605.3 684.7
Goodwill 329.2 327.6 417.2
Other assets 2.3 0.0 0.0
Total assets 1,418.8 1,404.6 1,562.7
Current liabilities:      
Accounts payable 20.5 21.7 33.3
Accrued liabilities 79.1 79.0 82.3
Current maturities of operating lease liabilities 13.6 13.5 0.0
Deferred revenue 32.7 32.8 2.2
Total current liabilities 145.9 147.0 117.8
Unrecognized tax benefits 30.5 23.5 21.7
Long-term deferred taxes 71.3 26.6 82.6
Long-term debt 224.8 224.4 233.5
Noncurrent operating lease liabilities 50.6 56.9 0.0
Other long-term liabilities 14.7 8.0 18.2
Total liabilities 537.8 486.4 473.8
Commitments and contingencies
Stockholders’ equity:      
Common stock, 75.4, 74.7 and 73.5 shares outstanding at December 31, 2020, June 30, 2020 and 2019, respectively 0.8 0.7 0.7
Additional paid-in capital 1,109.5 1,096.6 1,068.0
Accumulated other comprehensive income (loss) (2.3) (5.2) (5.4)
Retained earnings (accumulated deficit) (227.0) (173.9) 25.6
Total Myriad Genetics, Inc. stockholders' equity 881.0 918.2 1,088.9
Non-controlling interest 0.0 0.0 0.0
Total stockholders' equity 881.0 918.2 1,088.9
Total liabilities and stockholders’ equity $ 1,418.8 $ 1,404.6 $ 1,562.7